We are glad to welcome you at TRB’s Isokinetic Conference Workshop on Saturday June 4, 2022, to discuss the benefits of hyaluronic acid in high impact sports. The workshop will focus on early osteoarthritis in athletes and hyaluronic acid in tendinopathies. Join us in Lyon to learn more about these topics and exchange with our panel of speakers.
Saturday, 4 June 2022, 16:30-18:00, Room Bellecour 3
|16:30-16:35||Introduction||Dr. Kal Parmar|
|16:35-16:50||Hyaluronic acid: unique features and biomedical opportunities||Pauline Cipriano-Bonvin, PhD|
|16:50-16:55||Q&As||Pauline Cipriano-Bonvin, PhD|
|16:55-17:15||Early osteoarthritis in athletes: causes and management||Prof. Waqar Bhatti|
|17:15-17:25||Q&As||Prof. Waqar Bhatti|
|17:25-17:45||Hyaluronic acid in tendinopathies||Dr. Jörg Dünkel|
|17:45-17:55||Q&As||Dr. Jörg Dünkel|
|17:55-18:00||Conclusion and closing remarks||Dr. Kal Parmar|
We invite you to come visit our booth n°29/30 in Lyon at the Isokinetic Conference from 4th-6th June 2022. From relieving tendinopathy to accelerating post-arthroscopy recovery, we will be happy to share our expertise in relevant and exciting fields at this landmark event in Football Medicine & Orthopaedic Rehabilitation.
Come visit us from May 17th-19th at the CPhI North America 2022! We will be sharing our 40 years of experience in developing, producing, and promoting APIs, pharmaceutical products, and medical devices at this unique end-to-end pharma event in #Philadelphia.
We look forward to meeting and exchanging with you on-site or through the CPhI’s online platform.
Relieving pain and improving physical function is key in the treatment of osteoarthritis. This objective is particularly challenging in patients suffering from advanced OA, such as patients with Kellgren-Lawrence grade IV lesions or patients not eligible for joint replacement surgery. For long time, no new molecules have been successfully introduced in joint viscosupplementation. CM-chitosan is an innovative, naturally-derived glucosamine polysaccharide with lubricating and free-radical scavenging properties. Thanks to its unique structure, this molecule offers new opportunities in the treatment of advanced knee OA.
Please join us at our TRB Lunch Symposium on Friday 8th, chaired by Dr. Emmanuel Maheu, to learn more about the mechanism of action and the clinical efficacy of CM-chitosan. We are looking forward to meeting you there!
TRB Chemedica International will be present at the CPHI Worldwide Congress in Milan. Our team will be happy to welcome you on our booth. If you can’t make it, then let’s connect via the CPHI online platform which will be live from October 25 to November 19.
TRB Chemedica is pleased to invite you to the 6th International Symposium on Intra-Articular Treatment (ISIAT). We will be happy to meet you on our exhibition booth n°9.
Magnoglia, TRB’s subsidiary in Monaco, was the main sponsor of the fully digital neuroscience conference “L’homme cérébral” that took place on March 13, 2021. This event was organised by the Fondation pour l’Étude du Système Nerveux (FESN) and focused on the theme “Memory”.
TRB is pleased to support the first 100% virtual WCO-IOF-ESCEO e-congress which will take place from August 20 to 22 and available online until November 20, 2020. We are waiting for your visit at our booth in the virtual exhibition area!
TRB is also proud to host a Satellite Symposium entitled “Hyaluronic acid efficacy in osteoarthritis: beyond standard clinical parameters” which will be available online until November 20, 2020. This Symposium, chaired by Prof. Jean-Yves Reginster, University of Liège, will focus on the use of additional endpoints in clinical trials evaluating the efficacy of intra-articular hyaluronic acid such as our Ostenil products in osteoarthritis.
In addition, two posters summarising post-hoc analyses of TRB-sponsored clinical trials will be presented during the congress. Dr. Maheu, APHP Hôpital St-Antoine, Paris, will present the results of a post-hoc analysis of OSTP-EUR-10-01, a study published last December in PLoS One. This analysis compares the various definitions of responders that can be used in osteoarthritis (PASS, OMERACT-OARSI, MCII) and aimed at identifying predictive factors of a better response following intra-articular injection of hyaluronic acid.
The second poster is focusing on diacerein, a symptomatic slow-acting drug for osteoarthritis (SYSADOA). Prof. Jean-Pierre Pelletier, University of Montréal Hospital Research Centre, will discuss a post-hoc analysis of the DISSCO trial (A multicentre study on the effect of DIacerein on Structure and Symptoms versus Celecoxib in Osteoarthritis) aimed at exploring the influence of patient age on the magnitude of response to treatment with diacerein. Data revealed no differences between the efficacy and safety profile of diacerein in knee osteoarthritis patients younger or older than 65 years of age.
We are looking forward to participating in the first virtual WCO-IOF-ESCEO congress and hope that you share our excitement!
TRB Chemedica International was one of the proud sponsors of the conference “L’homme cérébral” organized by the Fondation pour l’étude du Système Nerveux on the 30th of March 2019 in Monaco.
You are about to leave the TRB corporate website. This link will take you to a local TRB website. Medical practices and regulations can be different from one country to another.
As a result, the medical information provided in the site which you are going to visit may not be appropriate for product use in your country.CONTINUE